Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups

RCT (n=287) found histology-tailored neoadjuvant chemotherapy (NC) was not linked to better disease-free or overall survival, suggesting standard anthracycline plus ifosfamide NC should remain regimen of choice whenever NC is used in this population.

Journal of Clinical Oncology